Background: CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor (TNFR) superfamily. Activated but not resting T and B cells express the CD30 protein. CD30 can regulate lymphocyte proliferation and may also play an important role in human immunodeficiency virus replication. As a regulator of apoptosis, the CD30 protein induces cell death or proliferation depending on the cell type and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protects the body against autoimmunity. CD30 protein expression is increased in several hematological malignancies, including Reed-Sternberg cells in Hodgkin disease (HD), anaplastic large cell lymphoma (ALCL), and non-Hodgkin lymphomas (NHL) and CD30 subsets. is also associated with leukocytes in patients with chronic inflammatory diseases, including lupus erythematosus, asthma, rheumatoid arthritis, and atopic dermatitis (AD)..The KRIBIOLISA Inhibitor Assay Kits available enable researchers to test the inhibitory effects of various compounds on specific enzymes at a higher output. These assays can help identify or characterize enzyme inhibitors, which is important in early drug discovery and development. They can also be useful in characterizing enzyme activity. These Inhibitor assay kits contain a known inhibitor as a control.
This Assay kit is designed to facilitate the identification and characterization of CD30 pathway inhibitors.
Assay Features include:
– Ready to use protocol with pre-coated breakapart wells for ease of use
– Standardisation and High Reproducibility
– Lot to Lot Consistency
– Accuracy and Precision
Validated against seven points for a Gold Ring Standard Quality – the benchmark sign for Krishgen quality.
The kits are used for assessing the specific biomarker in samples analyte which may be serum, plasma, biological fluids and cell culture supernatant.
Unlike competitor assays available, we offer pre-coated ready-to-use assays to ensure high level of reproducibility and accuracy.